Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Serum S100A6, S100A8, S100A9 and S100A11 proteins in colorectal neoplasia: results of a single centre prospective study

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F20%3A10407149" target="_blank" >RIV/00216208:11150/20:10407149 - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/00179906:_____/20:10407149

  • Výsledek na webu

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=WodGc-JQSZ" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=WodGc-JQSZ</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1080/00365513.2019.1704050" target="_blank" >10.1080/00365513.2019.1704050</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Serum S100A6, S100A8, S100A9 and S100A11 proteins in colorectal neoplasia: results of a single centre prospective study

  • Popis výsledku v původním jazyce

    S100 proteins are involved in biological events related to colorectal carcinogenesis. Aim of this prospective study was to assess serum concentration of S100A6, A8, A9 and A11 proteins in patients with colorectal neoplasia. Eighty-four subjects were enrolled: 20 controls (average risk population with normal findings on colonoscopy; 7 men, 13 women, age 23-74, mean 55 +/- 14), 20 patients with non-advanced colorectal adenoma (non-AA, 10 men, 10 women, age 41-82, mean 62 +/- 11), 22 with advanced colorectal adenoma (AA, 15 men, 7 women, age 49-80, mean 64 +/- 8) and 22 with colorectal cancer (CRC, 12 men, 10 women, age 49-86, mean 69 +/- 10). Peripheral venous blood was obtained. Serum S100 proteins were investigated by enzyme immunoassay technique. Serum S100A6 was significantly lower in CRC (mean 8530 +/- 4743 ng/L), p = .035 compared to controls (mean 11308 +/- 2968 ng/L). Serum S100A8 was significantly higher in AA (median 11955 ng/L, IQR 2681-34756 ng/L), p = .009 and in CRC (median 27532 ng/L, IQR 6794-35092 ng/L), p &lt; .001 compared to controls (median 2513 ng/L, IQR 2111-4881 ng/L). Serum S100A9 concentrations did not differ between any tested group and controls, p &gt; .05. Serum concentration of S100A11 was significantly lower in non-AA (mean 3.5 +/- 2.4 mu g/L), p = .004 and in CRC (mean 3.4 +/- 2.4 mu g/L), p = .002 compared to controls (mean 5.9 +/- 2.5 mu g/L). Sensitivity and specificity for S100A8 protein in patients with CRC were 94% and 73%; positive predictive value 68% and negative predictive value 95%. Patients with colorectal neoplasia have significantly lower serum S100A6 and S100A11 levels, significantly higher S100A8 and unaltered serum S100A9 levels.

  • Název v anglickém jazyce

    Serum S100A6, S100A8, S100A9 and S100A11 proteins in colorectal neoplasia: results of a single centre prospective study

  • Popis výsledku anglicky

    S100 proteins are involved in biological events related to colorectal carcinogenesis. Aim of this prospective study was to assess serum concentration of S100A6, A8, A9 and A11 proteins in patients with colorectal neoplasia. Eighty-four subjects were enrolled: 20 controls (average risk population with normal findings on colonoscopy; 7 men, 13 women, age 23-74, mean 55 +/- 14), 20 patients with non-advanced colorectal adenoma (non-AA, 10 men, 10 women, age 41-82, mean 62 +/- 11), 22 with advanced colorectal adenoma (AA, 15 men, 7 women, age 49-80, mean 64 +/- 8) and 22 with colorectal cancer (CRC, 12 men, 10 women, age 49-86, mean 69 +/- 10). Peripheral venous blood was obtained. Serum S100 proteins were investigated by enzyme immunoassay technique. Serum S100A6 was significantly lower in CRC (mean 8530 +/- 4743 ng/L), p = .035 compared to controls (mean 11308 +/- 2968 ng/L). Serum S100A8 was significantly higher in AA (median 11955 ng/L, IQR 2681-34756 ng/L), p = .009 and in CRC (median 27532 ng/L, IQR 6794-35092 ng/L), p &lt; .001 compared to controls (median 2513 ng/L, IQR 2111-4881 ng/L). Serum S100A9 concentrations did not differ between any tested group and controls, p &gt; .05. Serum concentration of S100A11 was significantly lower in non-AA (mean 3.5 +/- 2.4 mu g/L), p = .004 and in CRC (mean 3.4 +/- 2.4 mu g/L), p = .002 compared to controls (mean 5.9 +/- 2.5 mu g/L). Sensitivity and specificity for S100A8 protein in patients with CRC were 94% and 73%; positive predictive value 68% and negative predictive value 95%. Patients with colorectal neoplasia have significantly lower serum S100A6 and S100A11 levels, significantly higher S100A8 and unaltered serum S100A9 levels.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30219 - Gastroenterology and hepatology

Návaznosti výsledku

  • Projekt

  • Návaznosti

    S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Ostatní

  • Rok uplatnění

    2020

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    Scandinavian Journal of Clinical and Laboratory Investigation

  • ISSN

    0036-5513

  • e-ISSN

  • Svazek periodika

    80

  • Číslo periodika v rámci svazku

    3

  • Stát vydavatele periodika

    NO - Norské království

  • Počet stran výsledku

    6

  • Strana od-do

    173-178

  • Kód UT WoS článku

    000503604700001

  • EID výsledku v databázi Scopus

    2-s2.0-85076916153